Stop wasting hours on dense SEC filings. Get AI-powered summaries of any SEC Filings in seconds. Understand key insights and risks, fast.
Currently we only process Form 8-K, 6-K, 3, 4, 144, Schedule 13D and Schedule 13G. We will support more forms in the future.
Filter by Form Type:
Industry:Biotechnologyβ
2026-04-10ATHE3Initial Statement of Beneficial OwnershipMEDIUM
Lawrence Bernard Gozlan, a director at ALTERITY THERAPEUTICS LTD (ATHE), has filed an initial statement of beneficial ownership. The filing, dated April 10, 2026, details holdings through Montoya Pty Ltd <Buttercup A/C>. Gozlan holds 4,545,555 ordinary shares indirectly. Additionally, he holds 1,515,152 listed options ...
Micro CapBiotechnology
2026-04-10ATHE3Julian Michael Babarczy Reports No Securities Ownership in Alterity Therapeutics
This Form 3 filing reports that Julian Michael Babarczy, a director of Alterity Therapeutics Ltd (ATHE), has no securities ownership in the company as of April 10, 2026. The filing indicates that Babarczy serves as a director but does not hold any ownership position in the company's securities. The filing was submitted...
Micro CapBiotechnology
2026-04-10ATHE3Notification of Ownership ChangeMEDIUM
This filing reports a change in beneficial ownership of securities for Peter Ashley Marks, a director at ALTERITY THERAPEUTICS LTD. The changes involve both derivative and non-derivative holdings. Specifically, there are listed options expiring on February 26, 2027, and unlisted options expiring on December 30, 2027. T...
Micro CapBiotechnology
2026-04-10AAPG3Form 3 Filing for Ascentage Pharma Group InternationalMEDIUM
This filing details restricted stock units (RSUs) granted to Jin Cao, Chief Accounting Officer of Ascentage Pharma Group International. Each RSU represents a contingent right to one Ordinary Share, vesting in four equal increments on November 26th of 2026, 2027, 2028, and 2029. The filing also includes a Power of Attor...
Mid CapBiotechnology
2026-04-10ALTERITY THERAPEUTICS LTD3Julian Michael Babarczy Reports No Securities Ownership in Alterity TherapeuticsDuplicate
This Form 3 filing reports that Julian Michael Babarczy, a director of Alterity Therapeutics Ltd (ATHE), has no securities ownership in the company as of April 10, 2026. The filing indicates that Babarczy serves as a director but does not hold any ownership position in the company's securities. The filing was submitted...
Micro CapBiotechnology
2026-04-10BLRX3Shaoyu Yan's Form 3 - Initial Statement of Beneficial Ownership for BioLineRx Ltd.
This is a Form 3 filing by Shaoyu Yan, who has become a director of BioLineRx Ltd. (NASDAQ: BLRX). The filing represents Yan's initial statement of beneficial ownership of securities in the company, as required when a person becomes a director, officer, or beneficial owner of more than 10% of a class of equity securiti...
Nano CapBiotechnology
2026-04-10ASCENTAGE PHARMA GROUP INTERNATIONAL3Form 3 Filing for Ascentage Pharma Group InternationalDuplicateMEDIUM
This filing details restricted stock units (RSUs) granted to Jin Cao, Chief Accounting Officer of Ascentage Pharma Group International. Each RSU represents a contingent right to one Ordinary Share, vesting in four equal increments on November 26th of 2026, 2027, 2028, and 2029. The filing also includes a Power of Attor...
Mid CapBiotechnology
Sponsored
2026-04-10IPSC3Power of Attorney for Martin Patrick Murphy
This filing is an exhibit detailing a Power of Attorney granted by Martin Patrick Murphy, a director at Century Therapeutics, Inc. (IPSC). The document, dated December 9, 2025, and effective April 10, 2026, appoints Brent Pfeiffenberger, Douglas Carr, and Gregory Russotti as attorneys-in-fact. They are authorized to ex...
Small CapBiotechnology